Brittany Lovely | Authors


RLY-4008 Shows DCR of 100% in FGFR+ Cholangiocarcinoma

September 11, 2022

A novel FGFR inhibitor, RLY-4008, induced high response rates and encouraging durability in patients with FGFR inhibitor–naïve cholangiocarcinoma harboring an FGFR2 fusion or rearrangement, according to data from the phase 1/2 ReFocus trial presented at the 2022 ESMO Congress.

Updated Results Support Efficacy of Trastuzumab Deruxtecan in Metastatic Gastric/GEJ Cancer

September 11, 2022

New results from the DESTINY-Gastric02 study include responses, survival data for patients receiving trastuzumab deruxtecan for with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Dalpiciclib Improves PFS in the First-Line for HR+/HER2– Advanced Breast Cancer

September 09, 2022

The phase 2 DAWNA-2 trial of dalpiciclib plus letrozole or anastrozole led to a reduced the risk of disease progression vs chemotherapy alone in patients with treatment-naïve, hormone receptor–positive, HER2-negative advanced breast cancer.